Read by QxMD icon Read

Onconephrology (Pediatric)

shared collection
13 papers 0 to 25 followers Onco nephrology in Pediatrics
By P O Pediatrics, Nephrology
Nicole L Drezner, Roger J Packer
Embryonal tumors represent a heterogeneous group of malignancies characterized by poorly differentiated cells and generally aggressive behavior. Although advances in survival rates have been made in several of these tumor types, including Wilms' tumor, retinoblastoma, and medulloblastoma, survival of patients with central nervous system (CNS) embryonal tumors, including primitive neuro-ectodermal tumors (PNETs) and atypical teratoid rhabdoid tumors (AT/RT), are particularly poor. Advancing molecular analysis techniques and the development of gene expression profiles has led to the formulation of different subdivisions within many of the umbrella CNS tumor groups with clinical and prognostic implications...
January 2016: Translational pediatrics
Tomohiko Sasaki, Satoru Motoyama, Atsushi Komatsuda, Hiroyuki Shibata, Yusuke Sato, Kei Yoshino, Akiyuki Wakita, Hajime Saito, Akira Anbai, Mario Jin, Yoshihiro Minamiya
INTRODUCTION: We experienced two esophageal cancer patients who developed severe acute renal failure after neoadjuvant chemotherapy with cisplatin and 5-fluorourasil. PRESENTATION OF CASE: After administration of cisplatin, their serum creatinine increased gradually until they required hemodialysis and their renal failure was permanent. In both cases, renal biopsy examination indicated partial recovery of the proximal tubule, but renal function did not recover. After these events, one patient underwent definitive radiotherapy and the other underwent esophagectomy for their esophageal cancers, while continuing dialysis...
2016: International Journal of Surgery Case Reports
Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko
BACKGROUND: In this study we assessed the efficacy of nephron-sparing surgery and the changes in renal function after surgery in patients with solitary kidneys. PATIENTS AND METHODS: From January 2000 to January 2015, 50 patients with solitary kidneys underwent partial nephrectomy for renal cancer. In 34 of the patients the contralateral kidneys had been removed previously because of renal tumor. The mean age of the patients was 62 ± 10 years. There were 15 women and 35 men...
June 2016: Clinical Genitourinary Cancer
Alexander Reshetnik, Christian Scheurig-Muenkler, Markus van der Giet, Markus Tölle
A young patient develops cerebral posttransplant lymphoproliferative disorder. Despite concurrent significantly impaired transplant kidney function use of add-on high-flux hemodialysis for additional clearance made the administration of high-dose methotrexate feasible in this patient without occurence of acute chronic kidney failure and significant hematological toxicity.
November 2015: Clinical Case Reports
Albert Q Lam, Benjamin D Humphreys
AKI is common in patients with cancer, and it causes interruptions in therapy and increased hospital length of stay, cost, and mortality. Although cancer patients are susceptible to all of the usual causes of AKI in patients without cancer, there are a number of AKI syndromes that occur more frequently or are unique to this patient population. AKI also confers substantially increased risk of short-term death, and the ability to reverse AKI portends a better outcome in some cancers, such as multiple myeloma...
October 2012: Clinical Journal of the American Society of Nephrology: CJASN
Abdulla K Salahudeen, Joseph V Bonventre
Renal diseases in patients with cancer have many unique features, and often these diseases require specialized approaches. Newer cancer therapy has increased cancer cure rate and survival time, but such benefit is not fully realized, partly because of therapy-associated toxicities. Fluid and electrolyte abnormalities are very common in patients with cancer, as are acute and chronic kidney injury. With the evolving complexities of newer cancer therapies, a comprehensive team approach is becoming necessary. It is essential for nephrologists to be informed and involved in cancer care...
January 2013: Journal of the American Society of Nephrology: JASN
Zeenat Yousuf Bhat, Pravit Cadnapaphornchai, Kevin Ginsburg, Milani Sivagnanam, Shamit Chopra, Corey K Treadway, Ho-Sheng Lin, George Yoo, Ammar Sukari, Mona D Doshi
Acute kidney injury (AKI) is a well-known complication of cisplatin-based chemotherapy; however, its impact on long-term patient survival is unclear. We sought to determine the incidence and risk factors for development of cisplatin-associated AKI and its impact on long-term renal function and patient survival. We identified 233 patients who received 629 cycles of high-dose cisplatin (99±9mg/m2) for treatment of head and neck cancer between 2005 and 2011. These subjects were reviewed for development of AKI...
2015: PloS One
Ahmad Ahmadzadeh, Heshmatollah Shahbazian, Neda Safapour, Mehri Tulabi, Sepideh Zandifar
INTRODUCTION: Cisplatin is an efficient chemotherapeutic drug used for the treatment of different cancers. Clinical trials represents cisplatin-induced nephrotoxicity in a dose dependent manner. OBJECTIVES: This study aimed to compare the effects of 1-day treatment regimen with cisplatin on renal function, potassium, calcium, magnesium and uric acid in patients with gastric and lung cancer compared with 2-day divided cisplatin treatment regimen to suggest appropriate management for decrease nephrotoxic effects and >electrolyte abnormalities...
2015: Journal of Renal Injury Prevention
Małgorzata Janeczko, Ewa Niedzielska, Wojciech Pietras
BACKGROUND: Wilms' tumor is the most common kidney cancer in children. Treatment consists of pre- and post-operative chemotherapy, surgery and in some cases radiotherapy. The treatment of nephroblastomas is very effective. Hence, the population of adult patients cured of this cancer in their childhood is steadily growing, generating a need for long-term health assessment, including renal function, due to the specifications of the therapy and the location of the tumor. OBJECTIVES: The aim of the study was to evaluate nephrological complications after treatment for nephroblastoma...
May 2015: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
H Boer, J H Proost, J Nuver, S Bunskoek, J Q Gietema, B M Geubels, R Altena, N Zwart, S F Oosting, J M Vonk, J D Lefrandt, D R A Uges, C Meijer, E G E de Vries, J A Gietema
BACKGROUND: The success of cisplatin-based (Platinol, Bristol-Myers Squibb Company, New York, NY, USA) chemotherapy for testicular cancer comes at the price of long-term and late effects related to healthy tissue damage. We assessed and modelled serum platinum (Pt) decay after chemotherapy and determined relationships between long-term circulating Pt levels and known late effects. PATIENTS AND METHODS: In 99 testicular cancer survivors, treated with cisplatin-based chemotherapy, serum and 24-h urine samples were collected during follow-up (1-13 years after treatment)...
November 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Yasuhiro Kidera, Hisato Kawakami, Tsutomu Sakiyama, Kunio Okamoto, Kaoru Tanaka, Masayuki Takeda, Hiroyasu Kaneda, Shin-ichi Nishina, Junji Tsurutani, Kimiko Fujiwara, Morihiro Nomura, Yuzuru Yamazoe, Yasutaka Chiba, Shozo Nishida, Takao Tamura, Kazuhiko Nakagawa
BACKGROUND: Nephrotoxicity remains a problem for patients who receive cisplatin chemotherapy. We retrospectively evaluated potential risk factors for cisplatin-induced nephrotoxicity as well as the potential impact of intravenous magnesium supplementation on such toxicity. PATIENTS AND METHODS: We reviewed clinical data for 401 patients who underwent chemotherapy including a high dose (≥60 mg/m2) of cisplatin in the first-line setting. Nephrotoxicity was defined as an increase in the serum creatinine concentration of at least grade 2 during the first course of cisplatin chemotherapy, as assessed on the basis of National Cancer Institute Common Terminology Criteria for Adverse Events version 4...
2014: PloS One
Hassan Izzedine
Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity?...
2014: International Journal of Nephrology
Eric P Cohen, Jean-Marie Krzesinski, Vincent Launay-Vacher, Ben Sprangers
No abstract text is available yet for this article.
November 2015: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"